Cautious Outlook for Iovance Biotherapeutics Amid Amtagvi Sales Challenges

Iovance Biotherapeutics (IOVA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Dai from UBS maintained a Hold rating on the stock and has a $2.00 price target.

David Dai has given his Hold rating due to a combination of factors affecting Iovance Biotherapeutics. The company’s recent performance, particularly the lower-than-expected sales of Amtagvi in the first quarter of 2025, has raised concerns. The sales figures fell short of expectations, prompting a reduction in the full-year guidance, which suggests a slower-than-anticipated adoption of Amtagvi.
The challenges appear to stem from issues with activating smaller authorized treatment centers, which face obstacles such as inadequate infrastructure, limited resources, and potential reimbursement challenges. Additionally, high dropout rates indicate problems with patient selection, necessitating further physician education. These factors contribute to uncertainty about Amtagvi’s near-term sales ramp, leading to a more cautious outlook and a downgraded price target.

In another report released on May 12, Truist Financial also downgraded the stock to a Hold with a $5.00 price target.